NASDAQ:NXL Nexalin Technology (NXL) Stock Price, News & Analysis $0.36 -0.01 (-3.22%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$0.36 +0.00 (+1.36%) As of 06/23/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Nexalin Technology Stock (NASDAQ:NXL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nexalin Technology alerts:Sign Up Key Stats Today's Range$0.36▼$0.3850-Day Range$0.32▼$0.6152-Week Range$0.31▼$2.00Volume55,256 shsAverage Volume458,107 shsMarket Capitalization$7.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Nexalin Technology, Inc. is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation. The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions. Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.AI Generated. May Contain Errors. Read More Nexalin Technology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreNXL MarketRank™: Nexalin Technology scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingNexalin Technology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNexalin Technology has received no research coverage in the past 90 days.Read more about Nexalin Technology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nexalin Technology is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nexalin Technology is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNexalin Technology has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nexalin Technology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.68% of the float of Nexalin Technology has been sold short.Short Interest Ratio / Days to CoverNexalin Technology has a short interest ratio ("days to cover") of 0.43, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nexalin Technology has recently increased by 94.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNexalin Technology does not currently pay a dividend.Dividend GrowthNexalin Technology does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentNexalin Technology has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Business Services companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nexalin Technology this week, compared to 2 articles on an average week.Search Interest5 people have searched for NXL on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Nexalin Technology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nexalin Technology insiders have not sold or bought any company stock.Percentage Held by Insiders25.26% of the stock of Nexalin Technology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.65% of the stock of Nexalin Technology is held by institutions.Read more about Nexalin Technology's insider trading history. Receive NXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nexalin Technology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NXL Stock News HeadlinesNexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s ...June 23 at 10:12 AM | finance.yahoo.comNexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ PlatformJune 23 at 8:30 AM | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Nexalin Overhauls Bylaws, Modernizes Corporate Governance FrameworkJune 17, 2026 | tipranks.comNexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across ...June 16, 2026 | markets.businessinsider.comNexalin Technology, Inc. Announces Acceptance of Clinical Abstracts Showcasing DIFS™ Treatment Efficacy at 2026 NYC Neuromodulation ConferenceJune 16, 2026 | quiverquant.comQNexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of LifeJune 16, 2026 | globenewswire.comNexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across ...June 10, 2026 | finance.yahoo.comSee More Headlines NXL Stock Analysis - Frequently Asked Questions How have NXL shares performed this year? Nexalin Technology's stock was trading at $0.5580 at the beginning of the year. Since then, NXL shares have decreased by 35.5% and is now trading at $0.3601. How were Nexalin Technology's earnings last quarter? Nexalin Technology, Inc. (NASDAQ:NXL) announced its quarterly earnings data on Friday, May, 8th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.02 million. Nexalin Technology had a negative net margin of 3,018.12% and a negative trailing twelve-month return on equity of 191.88%. When did Nexalin Technology IPO? Nexalin Technology (NXL) raised $14 million in an initial public offering (IPO) on Friday, September 16th 2022. The company issued 2,315,000 shares at a price of $5.00-$7.00 per share. How do I buy shares of Nexalin Technology? Shares of NXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nexalin Technology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nexalin Technology investors own include Meta Platforms (META), NVIDIA (NVDA), Faraday Future Intelligent Electric (FFIE), Intel (INTC), PayPal (PYPL), Advanced Micro Devices (AMD) and DoorDash (DASH). Company Calendar Last Earnings5/08/2026Today6/23/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (14m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NXL's financial health is in the Yellow zone, according to TradeSmith. NXL has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Technology Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:NXL CIK1527352 Webwww.nexalin.com Phone832-260-0222FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.22 million Net Margins-3,018.12% Pretax Margin-3,018.48% Return on Equity-191.88% Return on Assets-166.43% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio3.85 Sales & Book Value Annual Sales$300 thousand Price / Sales24.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book1.80Miscellaneous Outstanding Shares20,580,000Free Float15,383,000Market Cap$7.41 million OptionableNot Optionable Beta3.80 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:NXL) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nexalin Technology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nexalin Technology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
